(Source: AstraZeneca plc) 20 November 2015 AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company's new global R&D centre at the Cambridge Biomedical Campus. It will screen around 2 million chemical structures per target to find new compounds for disease targets. The partnerships, which will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids, include: A...
↧